Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism
- 19 September 2017
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 167 (6) , 410-417
Abstract
Screening for cancer in patients with unprovoked venous thromboembolism (VTE) often is considered, but clinicians need precise data on cancer prevalence, risk factors, and the effect of different types of screening strategies. To estimate the prevalence of occult cancer in patients with unprovoked VTE, including in subgroups of different ages or those that have had different types of screening. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to 19 January 2016. Prospective studies evaluating cancer screening strategies in adults with unprovoked VTE that began enrolling patients after 1 January 2000 and had at least 12 months of follow-up. 2 investigators independently reviewed abstracts and full-text articles and independently assessed risk of bias. 10 eligible studies were identified. Individual data were obtained for all 2316 patients. Mean age was 60 years; 58% of patients received extensive screening. The 12-month period prevalence of cancer after VTE diagnosis was 5.2% (95% CI, 4.1% to 6.5%). The point prevalence of cancer was higher in patients who had extensive screening than in those who had more limited screening initially (odds ratio [OR], 2.0 [CI, 1.2 to 3.4]) but not at 12 months (OR, 1.4 [CI, 0.89 to 2.1]). Cancer prevalence increased linearly with age and was 7-fold higher in patients aged 50 years or older than in younger patients (OR, 7.1 [CI, 3.1 to 16]). Variation in patient characteristics and extensive screening strategies; unavailability of long-term mortality data. Occult cancer is detected in 1 in 20 patients within a year of receiving a diagnosis of unprovoked VTE. Older age is associated with a higher cancer prevalence. Although an extensive screening strategy initially may detect more cancer cases than limited screening, whether this translates into improved patient outcomes remains unclear. None. (PROSPERO: CRD42016033371)Keywords
This publication has 23 references indexed in Scilit:
- Extensive Computed Tomography versus Limited Screening for Detection of Occult Cancer in Unprovoked Venous Thromboembolism: A Multicenter, Controlled, Randomized Clinical TrialSeminars in Thrombosis and Hemostasis, 2016
- Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trialThe Lancet Oncology, 2016
- Guidance for the prevention and treatment of cancer-associated venous thromboembolismJournal of Thrombosis and Thrombolysis, 2016
- Screening for Occult Cancer in Unprovoked Venous ThromboembolismNew England Journal of Medicine, 2015
- Screening for occult malignancy with FDG‐PET/CT in patients with unprovoked venous thromboembolismInternational Journal of Cancer, 2013
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Is extensive screening for cancer in idiopathic venous thromboembolism warranted?Journal of Thrombosis and Haemostasis, 2010
- Testing for occult cancer in patients with pulmonary embolism: Results from a screening program and a two-year follow-up surveyThrombosis Research, 2010
- Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?Annals of Internal Medicine, 2008
- Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trialJournal of Thrombosis and Haemostasis, 2004